A Patented Revolution for the Safe Treatment of Life Threatening Peanut Allergy
Welcome to Natafproseed Ltd., where we are dedicated to developing a groundbreaking treatment for life-threatening peanut allergies. Join us in our mission to provide a safer and more effective solution for allergy sufferers.
Treating Allergies, Empowering Lives
Transforming Lives Through a Proven Peanut Allergy Treatment
Imagine a world where a child can go to school without fear, where parents no longer live in constant anxiety, and where millions who suffer from life-threatening peanut allergies can finally breathe free. That world is within reach—and we’ve built the solution to get there.
​
Every three minutes, a food allergy reaction sends someone to the emergency room. Among these, peanut allergy is the most common—and the most dangerous. For millions worldwide, a single bite can mean a race against time.
But it doesn’t have to be this way.
​
Our solution is not just a hope—it's a proven, scalable treatment that’s already changing lives. We've developed a scientifically-backed, clinically-tested approach that retrains the immune system to tolerate peanuts, dramatically reducing the risk of severe reactions.
This isn't a temporary fix—it's a long-term transformation for individuals and families trapped by this invisible threat.
Our Vision
Freedom from food allergies—starting with peanuts, expanding to tree nuts. Safe. Natural. Life-changing.
The Global Food Allergy Epidemic
A Silent, Growing Public Health Crisis Affecting Millions
Global Impact
-
250–300 million people worldwide suffer from food allergies
-
Affects up to 10% of children and 4–6% of adults globally
-
1 in 13 U.S. children | 17M+ in Europe | Rapid rise across Asia and LMICs
Rising Danger.
-
Prevalence has doubled in 10–15 years.
-
200,000+ ER visits annually in the U.S. alone.
-
Every 3 minutes, someone is rushed to the ER due to food allergy.
-
Severe, life-threatening reactions (anaphylaxis) are increasing globally.
The Hidden Burden.
-
$25B+ in annual costs in the U.S. (healthcare, food, lost productivity).
-
Emotional and social toll: anxiety, isolation, lifestyle restrictions.
-
Schools, caregivers, and communities under constant strain.
​
Peanut Allergy: A Leading Threat
-
Most common cause of fatal allergic reactions
-
Affects 6M+ Americans, including 1.5M+ children in Europe
-
No cure; lifelong condition in most cases
-
Trace exposure can cause severe or fatal reactions
​
​​
Our Technology
1
The Development of the Mona Peanut
Introducing "The Mona Peanut," our newly developed non-GMO peanut variety, specially designed for Oral Immuno-Therapy (OIT). This innovative peanut offers a tailored solution to enhance treatment efficacy and improve patient outcomes. With its unique properties, The Mona Peanut represents the basis of a significant advancement in allergy treatment.
2
Special Formulation
We have meticulously formulated The Mona Peanut to harness its advantages and uniqueness. Our focus is on maximizing the benefits of this groundbreaking variety for effective allergy management. This careful formulation stage enhances the properties of the Mona Peanut to allow patients receive the best possible support in their treatment journey.
3
Secondary Formulation
We further formulate The Mona Peanut into a child-friendly and effective option to enhance the final Oral Immuno-Therapy treatment in different forms such as in the current form of a biscuit. This innovative proprietary technology also makes it easier for children to engage with their treatment. Our goal is to ensure that the allergy treatment is both effective, safe and accessible for young patients. We are committed to advancing treatment options with The Mona Peanut.
Revolutionizing Allergy Treatment
Our Innovative Approach
​
Our Breakthrough Technology for Peanut and Tree Nut Desensitization:
​
At the forefront of allergy science, our team has pioneered a groundbreaking, non-GMO therapeutic technology that offers real hope to millions living with life-threatening peanut and tree nut allergies.
Leveraging advanced agricultural innovation and proprietary food science, we have developed a unique, non-GMO peanut variety formulated through a special, patented and proprietary process that allows safe, gradual desensitization to peanut proteins.
​
This innovation has already demonstrated exceptional success in clinical trials, where young children previously highly allergic to peanuts were able—after completing our structured treatment protocol—to safely consume normal dietary amounts of peanut-containing foods.
​
Many participants achieved tolerance levels equivalent to multiple whole peanuts, marking a dramatic transformation in both medical safety and quality of life.
​
Our approach doesn’t stop with peanuts. Thanks to the versatility of our technological platform, we are extending this revolutionary technology to other major allergens, including almonds, cashews, and walnuts.
This means that families around the world may soon have access to safe, effective, and lasting relief from some of the most common and dangerous food allergies.
​
By combining proven clinical efficacy, natural non-GMO ingredients, and a patient-friendly, food-based delivery method, our solution empowers patients—not only to survive with their allergies, but to thrive without them.
We are not just treating allergies—we are redefining what's possible for millions of lives around the globe.
Clinical Trials
Exceptional Phase IIa Trial Results for Peanut Allergy Desensitization Protocol Using Mona Peanut Formulations
In a Phase IIa trial evaluating a 40-week oral immunotherapy protocol using Mona peanut formulations (delivered via cookies, pancakes, and spreads), 33 pediatric patients with confirmed peanut allergy (73% male; 55% under age 4) were enrolled.
​
Baseline: All had a Single Highest Tolerated Dose (SHTD) <100 mg peanut protein.
​
Completion Rate: 97% (32/33) completed the protocol—demonstrating strong adherence and tolerability.
​
6-Month Follow-Up: Mean tolerated dose increased to 9.5 g, enabling real-world consumption of peanut-containing foods.
​
These results demonstrate robust and sustained desensitization in a high-risk, early-age population and support further development in advanced clinical stages.
Meet the Team
Our mission is to commercialize our groundbreaking technology and obtain FDA approval. To ensure the success of this endeavor, our team is comprised of multidisciplinary seasoned professionals each bringing their expertise to the table. Together, we are committed to achieving our goals and allowing for those suffering from life threatening peanut to return to normal life.
Prof. Mona I Kidon
R&D Medical Director
Mona Kidon, is a Professor of Pediatrics in the faculty of medicine of the TEL Aviv university and the Director of Pediatric Allergy and the Food allergy research program at Safra children's hospital, Sheba medical center in TEL hashomer, Israel.
Dr. Ran Hohav PhD
R&D Advisor
​Ran is a senior Research Scientist at ARO,
Plant Sciences Institute, Department of Field and Vegetables Crops . Head, Department of Vegetables and Field Crops Research, atr ARO. Ran is a leading scienist and an expert peanut genetesist and breeder.
Dror Meir, Adv.
CEO - Founder
Dror is a seasoned entrepreneur with over 25 years of experience in successfully commercializing more than 30 ventures across diverse industries., Dror has consistently transformed innovative ideas into thriving businesses. He is also a licensed attorney and a member of the Israeli Bar Association, bringing a unique blend of legal expertise and business acumen to every endeavor.
Mor Sweil, Adv.
Director of Strategic Alliance, & Legal Affairs
Founder
Mor has assisted companies from various sectors of technology including medical and biotech and served as legal counsel to venture capital funds, private equity funds, governmental incubators and groups of including angel investors as well as served as board member at several technology companies.
Mor is qualified in and is a member of the Israeli & New York Bar Associations Holds a LLB (TLV) & LLM (Pennsylvania) in corporate, M&A, financing and securities.
Miriam Mangelus PhD, MBA
Chief Programs Officer
Miriam has 24 years in the pharmaceutical industry, leading programs from inception through all phases, including pharmacological studies, IND enabling programs, and Phase I-III clinical trials. Skilled in aligning scientific, executive, and business priorities to optimize company objectives.
Founded, licensed, secured funding, and forged partnerships with major pharmaceutical companies for a successful startup venture. Possesses robust analytical capabilities, excelling in opportunity identification, early-stage technology assessment, value enhancement roadmap creation, portfolio management, and efficient R&D team management to drive value creation cost-effectively. Prior to joining Nataf Miriam held management positions at Everads therapy, Tel Aviv Technology Transfer unit, Genta, Pharmos and other companies. Miriam holds a PHD in neurobiochemistry and MBA.
Adi Rasin
Senior Clinical Research Coordinator
Adi has vast experience in the management of Allergy and asthma Clinics including facilitating staff organization and human resource management, patient communication, customer relations and working alongside medical personnel. Adi work at Teva Pharmaceutical Industries Ltd. and was responsible amongst others for Employee and patient data management, dedicated databases , reviewing and filing proper documentation. Adi hold a BA in Human Resources Management from The college of Management Studies Rishon LeZion Israel.
Dr. Miron Livneh
Advisory Board
Miron was the former CEO of Pfizer Israel until 2021.
Dr. Livneh has more than 30 years of experience in the pharmaceutical industry and joined Pfizer in 1995 as the Director of Clinical Research. He served as the Medical Director at Glaxo - Israel; Director and Regional Medical Director of Pfizer's Global Research and Development Division and Senior Executive and Medical & Clinical VP at Endogun Medical Systems.
Dr. Livneh is a Doctor of Medicine (M.D.) from the Faculty of Medicine of the Technion in Haifa
Prof. Michal Sharon
Advisory Board
Michal is a Full Prof at the department of Biomolecular Sciences, Weizmann Institute of Science. Her research lies at the interface between chemistry and biology. She is recognized for her developments of novel native mass spectrometry approaches for addressing hitherto unexplored biological questions. Her lab mainly investigates large protein complexes involved in the protein degradation pathway. Her grants and awards include two successive ERC Starting grants and the ICRF Research Career Development Award. She received the Mass Spectrometry in the Life Sciences Award, of the European Mass Spectrometry Conference.
Dr. Menachem Ze'evi PhD
Advisory Board
Mendi is seasoned expert in biopharmaceutical companies.
Served as: PhiloGene, Inc. Co-Founder and President. Pluristem Therapeutics (CEO). Polyheal Ltd. a Clal Biotechnology Industries Ltd (CEO). Merck Serono (VP Technology and VP Operations Technical Support). Bio-Technology General Ltd. VP Production and Development and more.. Mendi holds a M.Sc., Microbiology Tel Aviv University. Ph.D Biochemistry Postdoctoral, Virology, Identification and in vitro translation of human beta interferom mRNA The Weizmann Institute of Science, Rockefeller University Post Doctoral Fellow, Molecular and Cell Biology.
Chef Itai Farkus
Advisory Board
Itai is an expert in food tech, an experienced Chef and social entrepreneur with expertise in executing complex projects from their inception to finished products and services. Experience with scale, impact and market readiness has established and consulted many food tech companies and enterprises such as, KITCHEN STUDIO -founder and CEO,
Exclusive partnership with Jamie Oliver’s “Food Revolution” – sole ambassador of the initiative in Israel.
Besties - founding partner and head chef.
PulpIT© Nutrition by Salvage - Founding partner
RILBITE- COO & founding partner
Mr. Nagai Katsumi
Advisory Board
Mr. Nagai, is a seasoned expert in business development of Israeli technologies in Japan and Asia with vast management experience. He served as the General Manager of Tel-Aviv Branch of Yamada International Europe GmbH, the Director of Marketing for Japan, Novawiz/Odigo Ltd. (Internet start-up company). Production and Quality Control Manager of Heatran Ltd., Factory Manager of Nature Beta Technologies Ltd. (Manufacturing Food Supplements), Daiko Denshi Tsushin Ltd. Computer Soft wear System Engineer (Fujitsu Group.). Mr. Nagai, holds a Bachelor degree in Nuclear Engineering.
Mr. Nis Agmon
Advisory Board
Nis an expert in Direct & Non Direct marketing & Sales. Growing businesses from initiation to maturity & revenue responsible for large scale business enterprises with unique experience in startup companies which have developed into successful large scale companies. Nis served many years (until 2021) as an Executive V.P. Resources Division Manager at Clal Insurance Enterprise Holdings. Senior Vice President with The Phoenix Insurance Company Ltd and many more. He successful establish Clal online business and Insurance Direct which have proven to be a success enterprises. Nis holds a Bachelor degree in Business Management.
Get in Touch
This innovative work has the potential to save lives and improve the quality of life for millions of children and adults worldwide.
Please Get in Touch, If you so wish and believe in our mission and wish to support our efforts, your contribution will help accelerate research, testing, and development.
* Please note: Natafproseed Ltd. is a private company. Contributions are not tax-deductible and do not provide financial returns. All funds will be used solely to advance our research and product development.
​
​